From: Alterations in gut microbiota and host transcriptome of patients with coronary artery disease
 | CAD | Control | p |
---|---|---|---|
(n = 31) | (n = 23) | ||
Age (years) | 63.97 ± 8.33 | 62.28 ± 6.84 | 0.419 |
Males (n, %) | 16 (51.61) | 12 (52.17) | 0.977 |
Smoker (n, %) | 15 (48.39) | 9 (39.13) | 0.614 |
Alcohol (n, %) | 14 (45.16) | 12 (52.17) | 0.713 |
Arterial hypertension (n, %) | 18 (58.06) | 16 (69.57) | 0.598 |
Diabetes mellitus (n, %) | 9 (29.03) | 5 (21.74) | 0.603 |
Hyperlipidemia (n, %) | 4 (9.68) | 3 (13.04) | 0.989 |
Family history of CAD (n, %) | 6 (19.35) | 2 (8.70) | 0.314 |
Syncope (n, %) | 1 (3.23) | 0 (0) | 0.389 |
Atrial fibrillation (n, %) | 2 (6.45) | 4 (17.39) | 0.233 |
Peripheral arterial disease (n, %) | 1 (3.23) | 1 (4.35) | 0.832 |
Leukocyte (× 109/L) | 6.26 ± 1.62 | 6.07 ± 1.91 | 0.782 |
Neutrophil (%) | 63.14 ± 7.51 | 61.82 ± 9.81 | 0.571 |
Lymphocyte (%) | 27.58 ± 6.57 | 29.08 ± 8.06 | 0.445 |
Hemoglobin (g/L) | 134.77 ± 16.11 | 137.04 ± 15.39 | 0.596 |
Platelet (× 109/L) | 217.94 ± 43.19 | 217.80 ± 60.99 | 0.992 |
Albumin (g/L) | 39.03 ± 3.23 | 39.33 ± 2.21 | 0.694 |
ALT (U/L) | 22.81 ± 11.30 | 18.25 ± 5.31 | 0.074 |
AST (U/L) | 23.55 ± 7.27 | 23.63 ± 4.45 | 0.962 |
Creatinine (umol/L) | 76.74 ± 18.39 | 73.03 ± 19.73 | 0.475 |
Uric acid (umol/L) | 310.35 ± 85.91 | 305.35 ± 81.14 | 0.829 |
Triglyceride (mmol/L) | 2.06 ± 1.87 | 1.53 ± 1.33 | 0.253 |
Cholesterol (mmol/L) | 4.13 ± 0.87 | 4.21 ± 0.93 | 0.736 |
High-density lipoprotein (mmol/L) | 1.05 ± 0.25 | 1.17 ± 0.27 | 0.099 |
Low-density lipoprotein (mmol/L) | 2.17 ± 0.68 | 2.24 ± 0.83 | 0.722 |
CKMB (U/L) | 14.26 ± 9.46 | 14.83 ± 4.91 | 0.788 |
cTNI (ug/L) | 0.05 ± 0.14 | 0.01 ± 0.00 | 0.168 |
Echocardiography | |||
 LVEF (%) | 64.53 ± 4.63 | 63.27 ± 8.30 | 0.494 |
Medication | |||
 ACEI (n, %) | 7 (22.58) | 3 (13.04) | 0.421 |
 ARB (n, %) | 10 (32.26) | 9 (39.13) | 0.674 |
 ARNI (n, %) | 3 (9.68) | 4 (17.39) | 0.436 |
 β-blocker (n, %) | 24 (77.42) | 12 (25.25) | 0.261 |
 Ivabradine (n, %) | 0 (0.00) | 2 (8.70) | 0.101 |
 MRA (n, %) | 7 (22.58) | 2 (8.70) | 0.217 |
 Antiplatelet drugs/A (nticoagulants (n, %) | 31 (100.00) | 23 (100.00) | 1.000 |
 Lipid lowering agents (n, %) | 28 (90.32) | 20 (86.96) | 0.897 |
 Coronary artery stenosis (%) | 84.58 ± 6.58 | 15.71 ± 1.35 |  < 0.01* |